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The conformation of the transcription factor TFIIB modulates the
response to transcriptional activators in vivo
Nicola A. Hawkes, Rachel Evans and Stefan G.E. Roberts
The general transcription factor TFIIB plays a crucial
role in the assembly of the transcriptional preinitiation
complex and has also been proposed as a target of
transcriptional activator proteins (reviewed in [1]). TFIIB
is composed of two domains which are engaged in an
intramolecular interaction that is disrupted upon
interaction with the activation domain of the
Herpesvirus VP16 protein in vitro [2,3]. The significance
of this event for transcriptional activation is not known,
however. The amino-terminal intramolecular interaction
domain is the most conserved region of TFIIB and plays
a role in transcription start-site selection [4–6]. In
addition, we have shown previously that the integrity of
this region is required for transcriptional activation
in vivo [4]. Here, we have defined a charge cluster at the
amino terminus of TFIIB that is required for
transcriptional activation in vivo. We found that this
domain determines the affinity of the TFIIB
intramolecular interaction and the ability of TFIIB to
interact with a transcriptional activation domain, but
not with components of the holoenzyme. Our results
suggest that the intramolecular interaction in TFIIB
regulates transcriptional activation in vivo.
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Results and discussion
We tested several TFIIB derivatives containing single and
double point mutations in the highly conserved amino-ter-
minal domain for their ability to support transcriptional
activation mediated by the VP16 activation domain in vivo
(Figure 1c). The reporter construct G5E4CAT was trans-
fected into human embryonic kidney 293 cells along
with an expression vector encoding amino acids 1–93 of
GAL4 fused to VP16 (GAL4–VP16), and either an
empty cytomegalovirus (CMV) expression vector or the
TFIIB derivatives indicated in Figure 1c under the
control of the CMV promoter. All of the TFIIB deriva-
tives were expressed at equivalent levels, as assessed by
immunoblotting. Total RNA was extracted and the E4
transcripts detected by primer extension. As we
observed with GAL4 activation region II (RII) [4],
TFIIB R66E but not TFIIB E51R inhibited transcrip-
tional activation by GAL4–VP16. TFIIB R66A also
inhibited transcriptional activation by GAL4–VP16, but
not to the same degree as TFIIB R66E. TFIIB R66K
did not significantly inhibit transcriptional activation by
GAL4–VP16, however, confirming the importance of a
charged residue at position 66. In addition, the
inhibitory effect of TFIIB R66E was reversed by the
second mutation E51R (E51R:R66E). Taken together
Figure 1
(a) Schematic illustration of TFIIB. The bars at the top indicate the
regions involved in both the intramolecular interaction and the
interaction with VP16. The sequence of amino-acid residues 36–70 is
shown below in the single-letter amino-acid code; highly conserved
residues are shaded. The amino acids mutated in this study (bold) are
indicated by arrows. N, amino terminus; C, carboxyl terminus. The two
direct repeats of TFIIB are indicated by the shaded regions containing
arrows and the plus signs indicate the charged residues of the basic
amphipathic helix. (b) Schematic diagram of the proposed effects of
the interaction with VP16 on TFIIB conformation. (c) Analysis of the
ability of the TFIIB mutants to support transcriptional activation by
GAL4–VP16 in vivo. Top panel, transcript analysis after transfection of
293 cells with the reporter G5E4CAT (2 µg), GAL4–VP16 (50 ng)
and the indicated TFIIB derivatives (2 µg; WT is wild-type TFIIB; see
Supplementary material). Lower panel, an immunoblot confirming
expression of the TFIIB derivatives in 293 cells.
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with the previous studies in yeast and our experiments
with the GAL4 RII activation domain, the data indicate
that a salt bridge between TFIIB residues E51 and R66
is required for transcriptional activation in vivo [4,6]. 
The mutant E51R, unlike TFIIB R66E, did not inhibit
transcriptional activation in vivo, suggesting that a more
complex mechanism may be involved. We therefore
tested whether the inhibitory effect of R66E could be
reversed by the substitution of an acidic residue other
than E51 with a basic residue. We substituted the highly
conserved residue D47 (Figure 1a) with lysine to
produce a double point mutant D47K:R66E, and tested
its effect on transcriptional activation by GAL4–VP16
in vivo. D47K reversed the inhibitory effect of R66E in a
manner similar to that observed with E51R. Thus, the
ability of TFIIB to support transcriptional activation
in vivo is dependent on the interplay of at least three
charged residues.
We next tested the ability of the TFIIB mutants to interact
with 35S-labelled GAL4–VP16 (Figure 2a) in a farwestern
assay identical to that previously used to monitor this inter-
action [2]. Equal amounts of recombinant wild-type TFIIB
and the mutants E51R, R66E and E51R:R66E were
resolved by SDS–PAGE, transferred to membrane and
probed with 35S-labelled GAL4–VP16 (Figure 2b). Binding
was assessed by autoradiography (upper panel) and quanti-
tation performed by phosphorimager analysis. The same
membrane was then immunoblotted with a monoclonal
antibody that recognises the T7 epitope tag at the carboxyl
terminus of all the derivatives (lower panel). The relative
affinities of wild-type TFIIB and the mutants for
GAL4–VP16 are shown graphically in Figure 2b after nor-
malisation against the signal quantified from the
immunoblot. Compared with wild-type TFIIB, E51R
showed a consistently small increase in its affinity for
GAL4–VP16 (1.7-fold). Strikingly, TFIIB R66E was signif-
icantly impaired in its ability to interact with GAL4–VP16
(10-fold). The affinity of the double point mutant TFIIB
E51R:R66E for GAL4–VP16 was similar to that of wild-
type TFIIB, however. Thus, the human TFIIB mutant
R66E is defective for interaction with an acidic activation
domain, consistent with the defect in supporting transcrip-
tional activation by acidic activators in vivo. Furthermore,
the defect in the VP16 interaction is reversed in
E51R:R66E, as is the transcription defect in vivo. 
The RAP30 subunit of the transcription factor TFIIF has
previously been shown to interact with TFIIB [7,8]. We
performed the same farwestern assay using 35S-labelled
RAP30 (Figure 2a) as the probe (Figure 2c). The mutants
E51R and E51R:R66E both showed a small increase in
affinity for RAP30. Significantly, in contrast to the effect
on interaction with GAL4–VP16, TFIIB R66E showed
only a slight decrease in affinity for RAP30. In addition, all
of the TFIIB mutants were able to associate with RNA
polymerase II (Pol II) in an immunoprecipitation assay
(Figure 2d). We conclude that TFIIB R66E is severely
and specifically compromised in its ability to interact with
GAL4–VP16 and this effect is reversed in the double
point mutant E51R:R66E. 
The amino terminus of human TFIIB (including the
region harbouring the above mutations) is dispensable for
the interaction with GAL4–VP16 [2]. Indeed, deletion of
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Figure 2
The TFIIB mutant R66E is specifically defective in its interaction with
GAL4–VP16. (a) Autoradiogram showing the 35S-labelled
GAL4–VP16 and RAP30 used in the farwestern analysis in (b,c).
(b) Upper panel, farwestern analysis (performed as described
previously [2]) of wild-type (WT) TFIIB or the indicated TFIIB derivatives
(100 ng; TFIIB derivatives were tagged with T7) with 35S-labelled
GAL4–VP16. Middle panel, the same membrane probed with anti-T7
tag monoclonal antibody; lower panel, graphical representation of the
farwestern data after normalisation to the immunoblot quantitation.
(c) As in (b) except that 35S-labelled RAP30 was the probe in the
farwestern assay. (d) The indicated TFIIB mutants (input) were
incubated with Pol II, followed by immunoprecipitation with anti-Pol II
antibodies (see Supplementary material). The recovery of the TFIIB
derivatives was assessed by immunoblotting with an anti-T7 antibody.
The control antibody was anti-immunoglobulin G antibody.
bb10e51.qxd  03/13/2000  02:12  Page 274
residues 4–85 of human TFIIB enhances the affinity for
VP16 (Figure 3a) [2]. This effect is due to the intramolecu-
lar interaction between the amino and carboxyl termini of
TFIIB, which competes with the interaction between
VP16 and the carboxy-terminal domain. We therefore con-
sidered the possibility that the defect in the interaction
between the human TFIIB mutant R66E and VP16 was
due to a modulation of the TFIIB intramolecular interac-
tion. Protein affinity chromatography was used to monitor
the interaction in trans between the TFIIB carboxy-termi-
nal domain and an immobilized glutathione-S-transferase
(GST) fusion protein of TFIIB residues 1–124 (Figure 3b).
As seen previously, the carboxy-terminal domain of TFIIB
stably interacted with the immobilised amino terminus [2].
The immobilised TFIIB amino terminus containing the
mutation E51R also interacted with the carboxyl terminus.
Significantly, the amino-terminal domain mutant R66E
interacted with the carboxy-terminal domain with
enhanced affinity and this effect was reversed in the
double mutant E51R:R66E. Taken together with the far-
western data, we conclude that the human TFIIB mutant
R66E exhibits a higher affinity in its intramolecular inter-
action and that this in turn reduces the affinity for VP16. 
Our transfection experiments showed that the charge of
TFIIB residue R66 was the critical requirement to support
transcriptional activation by GAL4–VP16. Farwestern
analysis showed that TFIIB R66A was defective in its
ability to interact with GAL4–VP16, but not to the same
extent as R66E (Figure 4a). R66K, however, showed a 2.7-
fold enhancement in affinity for GAL4–VP16 compared
with wild-type TFIIB, suggesting a weakening of the
intramolecular interaction. Thus, these data demonstrate
that the charge of TFIIB residue 66 is critical in determin-
ing the ability of TFIIB to interact with VP16 and, hence,
also the affinity of the intramolecular interaction. Moreover,
the VP16 interaction defect was also reversed in the double
mutant D47K:R66E. Significantly, these data parallel the
ability of the TFIIB derivatives to support transcriptional
activation in vivo. We therefore conclude that TFIIB
residues D47, E51 and R66 coordinately regulate the affin-
ity of the intramolecular interaction between the amino-
and carboxy-terminal domains of TFIIB and that this regu-
lates the response to transcriptional activators in vivo.
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Figure 3
The TFIIB mutations affect the interaction between the amino- and
carboxy-terminal domains of TFIIB. (a) Farwestern analysis of a TFIIB
mutant lacking amino-acid residues 4–85 (∆4–85). The probe was
35S-labelled GAL4–VP16 as in Figure 2b. (b) The T7-tagged
carboxyl terminus of TFIIB was incubated with agarose beads
coupled to GST fusion proteins of the indicated amino-terminal TFIIB
derivatives (1 µg) as described previously [2]. A gel stained with
Coomassie blue is shown below. Bound TFIIB carboxy-terminal
domain was detected by immunoblotting with anti-T7 monoclonal
antibody. The first lane (I) shows 5% of the input TFIIB carboxyl
terminus used in the assay.
Figure 4
(a) TFIIB mutants that are defective in transcriptional activation in vivo
also affect the interaction with GAL4–VP16. Farwestern analysis with
35S-labelled GAL4–VP16 (as in Figure 2b) using wild-type (WT) TFIIB
or the indicated TFIIB derivatives. (b) Model depicting the mechanism
by which TFIIB R66E inhibits transcriptional activation in vivo. In the
presence of wild-type TFIIB (left), the activator recruits the holoenzyme
by engaging contact with TFIIB. Holoenzymes containing TFIIB R66E
(right) are not efficiently recruited to the promoter because the
activator–TFIIB interaction is compromised by the increased affinity of
the TFIIB intramolecular interaction. 
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Previous studies used biochemical assays to show that
VP16 can disrupt the TFIIB intramolecular interaction [2].
Here, we have provided evidence that the TFIIB intramol-
ecular interaction regulates transcriptional activation in vivo.
A role for the amino terminus of TFIIB in transcriptional
activation is not without precedent. A recent study
described a mutant of yeast TFIIB (S53P) that is defective
in supporting transcriptional activation by Pho4 even
though the amino terminus of TFIIB is dispensable for the
interaction [9]. In addition, a study by Knaus et al. [10]
found that overexpression of a yeast protein similar to the
mammalian coactivator PC4 (SUB1) was able to suppress
the slow growth phenotype observed with the yeast TFIIB
mutant R78H. A recent report using an R64E mutant of
yeast TFIIB suggested that the intramolecular interaction
enhances assembly of a TATA-binding protein
(TBP)–TFIIB–promoter complex, although a comparable
human mutant (R53E) was not as effective [11]. Consistent
with this, we have found that human TFIIB R66E forms a
TBP–TFIIB–promoter complex with a similar affinity to
wild-type TFIIB (see Supplementary material). 
The fact that TFIIB R66E inhibits transcriptional activa-
tion in vivo strongly suggests that it is engaging in interac-
tions with components of the transcription machinery and
preventing their utilisation in transcriptional activation. We
have shown that TFIIB R66E is not significantly compro-
mised in its ability to interact with either Pol II or TFIIF
in vitro. Our data therefore support the idea that, in a living
cell, TFIIB is complexed with the Pol II holoenzyme. We
propose that the mutant R66E is able to displace wild-type
TFIIB from the holoenzyme in vivo. Consequently, this
would prevent activator-mediated recruitment of the
holoenzyme through TFIIB contact (Figure 4b). This
model would be consistent with several previous observa-
tions. Firstly, recruitment of the holoenzyme has been
reported to be a crucial function of transcriptional activa-
tion domains [12,13]. Secondly, TFIIB is able to elicit tran-
scriptional activation when linked to a DNA-binding
domain in ‘activator-bypass’ experiments that function by
holoenzyme recruitment [14–16]. Finally, overexpression
of TFIIB mutants unable to interact with Pol II/TFIIF do
not inhibit transcription in yeast, strongly suggesting that
assembly of TFIIB into the holoenzyme is required for the
recruitment of TFIIB to the promoter in vivo [15]. 
It was originally speculated that the TFIIB intramolecular
interaction might modulate the association of TFIIB with
TFIIF and Pol II [2]. Our present work suggests that this
is not the case. The data suggest that one function may be
to modulate the response to activator proteins. This would
be consistent with a previous report which showed that
raising the concentration of a TFIIB-containing yeast
holoenzyme in vitro can overcome the requirement for an
activator at the adenovirus E4 promoter [12]. The
content/conformational status of the holoenzyme may
define the affinity of the TFIIB intramolecular interac-
tion, and thus modulate access to TFIIB by a given activa-
tion domain. In summary, our results provide evidence
that the conformational status of components of the tran-
scription machinery plays a crucial role in the regulation of
gene expression.
Supplementary material
Supplementary material including additional methodological detail and a
figure showing that TFIIB derivatives form a TBP–TFIIB–promoter
complex is available at http://current-biology.com/supmat/supmatin.htm.
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